Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 1,729 Shares

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the transaction, the chief executive officer directly owned 927,309 shares in the company, valued at $38,297,861.70. This represents a 0.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $41.31 on Wednesday. The business has a 50-day moving average of $33.51 and a 200 day moving average of $28.05. Oruka Therapeutics, Inc. has a fifty-two week low of $5.49 and a fifty-two week high of $42.41. The firm has a market cap of $2.05 billion, a P/E ratio of -22.21 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. As a group, research analysts predict that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on ORKA shares. Leerink Partners upped their price target on shares of Oruka Therapeutics from $58.00 to $86.00 and gave the company an “outperform” rating in a research note on Monday. Wall Street Zen raised shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. Stifel Nicolaus increased their target price on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. BTIG Research reaffirmed a “buy” rating and issued a $73.00 price target on shares of Oruka Therapeutics in a report on Friday, March 13th. Finally, UBS Group assumed coverage on Oruka Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target for the company. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $59.60.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds have recently bought and sold shares of ORKA. Royal Bank of Canada increased its holdings in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares during the period. Kennedy Capital Management LLC boosted its holdings in Oruka Therapeutics by 0.9% in the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after purchasing an additional 420 shares during the period. Russell Investments Group Ltd. boosted its holdings in Oruka Therapeutics by 35.0% in the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after purchasing an additional 788 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Oruka Therapeutics by 62.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after purchasing an additional 904 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Oruka Therapeutics during the 4th quarter valued at $37,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Key Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Leerink Partners raised its price target from $58 to $86 and kept an “outperform” rating — a very bullish re-rate that signals substantial upside from current levels. Leerink Raises PT to $86
• Positive Sentiment: Multiple firms reiterated or raised ratings/targets this week (BTIG reiterated Buy; Wedbush reiterated Outperform; Guggenheim reiterated Buy; another outlet raised a $50 target), reinforcing analyst conviction and likely driving buying interest. BTIG Reiterates Buy Wedbush Outperform Guggenheim Buy PT Raised to $50
• Neutral Sentiment: Zacks notes the average of Wall Street price targets implies roughly ~41.5% upside — a helpful summary of consensus upside but one that Zacks cautions is an imperfect predictor on its own. Zacks Analyst PT Note
• Negative Sentiment: Several insiders sold shares on March 16: Joana Goncalves sold 7,641 shares (avg $40.91) — filing: Goncalves Form 4; SVP Arjun Agarwal sold 395 shares (avg $41.30) — filing: Agarwal Form 4; CEO Lawrence Klein sold 1,729 shares (avg $41.30) — filing: Klein Form 4. Multiple same-day executive sales can create short-term selling pressure or investor uncertainty even if motives include diversification.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.